PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21844014-10	2011	RESULTS: The combination of riluzole with sorafenib exhibited enhanced antitumor activities in GRM1-expressing melanoma cells harboring either wild-type or mutated B-RAF.	Sorafenib	42-51	glutamate metabotropic receptor 1	Homo sapiens	95-99	
21844014-11	2011	The combination of riluzole with PLX4720 showed lessened efficacy compared with the combination of riluzole and sorafenib in suppressing the growth of GRM1-expressing cells harboring the B-RAF(V600E) mutation.	Sorafenib	112-121	glutamate metabotropic receptor 1	Homo sapiens	151-155	
21844014-12	2011	CONCLUSIONS: The combination of riluzole with sorafenib seems potent in suppressing tumor proliferation in vitro and in vivo in GRM1-expressing melanoma cells regardless of B-RAF genotype and may be a viable therapeutic clinical combination.	Sorafenib	46-55	glutamate metabotropic receptor 1	Homo sapiens	128-132